Erratum: Evaluation of molecular forms of PSA and human kallikrein 2 in predicting biochemical failure following radical prostatectomy (International Journal of Cancer (2009) 125 (659-663) DOI:10.1002/ijc.23983)

Bibliografske podrobnosti
Main Authors:	Wenske, S, Korets, R, Cronin, A, Vickers, A, Fleisher, M, Scher, H, Pettersson, K, Guillonneau, B, Scardino, P, Eastham, J, Lilja, H
Format:	Journal article
Jezik:	English
Izdano:	2010

Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy.
od: Wenske, S, et al.
Izdano: (2009)

Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum.
od: Steuber, T, et al.
Izdano: (2006)

Cochrane review of electronic cigarettes for smoking cessation (10.1002/14651858.CD010216.pub9)
od: Butler, A, et al.
Izdano: (2024)

Is anti-viral defence the evolutionary origin of mRNA turnover? (Comment on DOI 10.1002/bies.201600100).
od: Rehwinkel, J
Izdano: (2016)

Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy.
od: O'Brien, M, et al.
Izdano: (2009)

PSA is dead, long live PSA.
od: Vickers, A, et al.
Izdano: (2012)

Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses.
od: Ulmert, D, et al.
Izdano: (2012)

Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer.
od: Steuber, T, et al.
Izdano: (2007)

Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy.
od: Steuber, T, et al.
Izdano: (2007)

Processed data associated with the paper Dwyer, J. G., and P. A. O’Gorman (2017), Geophys. Res. Lett., doi:10.1002/2017GL072855
od: Dwyer, John, et al.
Izdano: (2017)

Which drug is effective and safe for acute malaria in pregnancy? Reviewing the evidence (Drug Development Research (2010) 71, (56-68) DOI: 10.1002/ddr.20348)
od: McGready, R, et al.
Izdano: (2010)

Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.
od: Ulmert, D, et al.
Izdano: (2008)

Expression of prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2) in ileum and other extraprostatic tissues.
od: Olsson, A, et al.
Izdano: (2005)

Prostate cancer: estimating the benefits of PSA screening.
od: Vickers, A, et al.
Izdano: (2009)

Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication.
od: Vickers, A, et al.
Izdano: (2010)

P5 First screening round results of the ProScreen trial with PSA, kallikrein panel and MRI
od: A.S. Rannikko, et al.
Izdano: (2024-05-01)

Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival.
od: Helo, P, et al.
Izdano: (2009)

A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands.
od: Gupta, A, et al.
Izdano: (2010)

A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam.
od: Vickers, A, et al.
Izdano: (2010)

A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening.
od: Vickers, A, et al.
Izdano: (2011)

We need a better marker for prostate cancer. How about renaming PSA?
od: Vickers, A, et al.
Izdano: (2012)

Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer.
od: Klein, R, et al.
Izdano: (2010)

Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues.
od: Björk, T, et al.
Izdano: (2001)

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden.
od: Vickers, A, et al.
Izdano: (2008)

Commentary on Greenberg et al., “Prescribing anti‐amyloid immunotherapies to treat Alzheimer's disease: Fully informing patient decisions” [Alzheimer's Dement. 2023; 9(4):e12426. doi.org/10.1002/trc2.12426]
od: Carl V. Hill, et al.
Izdano: (2024-01-01)

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden
od: Scardino Peter T, et al.
Izdano: (2008-07-01)

1002. Cistanche deserticola: Orobanchaceae
od: Lei, D, et al.
Izdano: (2021)

The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease.
od: Becker, C, et al.
Izdano: (2001)

The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer.
od: Haese, A, et al.
Izdano: (2003)

Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.
od: Haese, A, et al.
Izdano: (2001)

Erratum: MHC-peptide-specific antibodies reveal inefficient presentation of an HLA-A*0201-restricted, Melan-A-derived peptide after active intracellular processing (European Journal of Immunology (2007) vol. 37 (7) 10.1002/eji.200636545)
od: Held, G, et al.
Izdano: (2008)

Copy number variants in the kallikrein gene cluster.
od: Pernilla Lindahl, et al.
Izdano: (2013-01-01)

Prostate kallikrein markers in diagnosis, risk stratification and prognosis.
od: Ulmert, D, et al.
Izdano: (2009)

Blood levels of free-PSA but not complex-PSA significantly correlates to prostate release of PSA in semen in young men, while blood levels of complex-PSA, but not free-PSA increase with age.
od: Sävblom, C, et al.
Izdano: (2005)

Role of hK2, free PSA, and complexed PSA measurements in the very early detection of prostate cancer.
od: Lilja, H
Izdano: (2001)

Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review.
od: Carlsson, S, et al.
Izdano: (2012)

Sensitive and specific immunodetection of human glandular kallikrein 2 in serum.
od: Becker, C, et al.
Izdano: (2000)

Taxonomic and Thematic Relatedness Ratings for 659 Word Pairs
od: Jon-Frederick Landrigan, et al.
Izdano: (2016-02-01)

Acute Appendicitis: An Audit of 663 Cases
od: Salim Khattak, et al.
Izdano: (2010-12-01)

Erratum: Analysis of Lyn/CD22 double-deficient B cells in vivo demonstrates Lyn- and CD22- independent pathways affecting BCR regulation and B cell survival (European Journal of Immunology (2005) vol. 35 (12) (3714) 10.1002/eji.200535247)
od: Ferry, H, et al.
Izdano: (2005)

Erratum: Evaluation of molecular forms of PSA and human kallikrein 2 in predicting biochemical failure following radical prostatectomy (International Journal of Cancer (2009) 125 (659-663) DOI:10.1002/ijc.23983)

Podobne knjige/članki

Podobne knjige/članki